

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 22230

Title: Pharmacological cyclin dependent kinase inhibitors

Reviewer's code: 00037474

Reviewer's country: Canada

Science editor: Jing Yu

Date sent for review: 2015-08-21 19:41

Date reviewed: 2015-09-11 01:47

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

In this manuscript, Balakrishnan and coll present a perspective concerning the potential use of pharmacological cyclin dependent kinase inhibitors for the treatment of colorectal cancer. Overall, I found this to be a good review. Here are a few suggestions and/or corrections which would improve the article: 1- Title: I think the term "pharmacological" should be specified in the title as follows: "Pharmacological cyclin dependent kinase inhibitors: Implications for colorectal cancer" and elsewhere in the text to distinguish them from cellular inhibitors. 2- The "Conflict-of-interest statement" should be completed. 3- Page 4, 2nd para.: Rewrite "(...) the battle against cancer is combatted and (...)" 4- Page 6, 2nd para.: It would seem pertinent to identify the main cellular forms of CDK inhibitors of the two classes. 5- Page 6, 2nd para.: The relatively abundant literature reporting the effects of cellular CDK inhibitors on growth arrest and tissue specific gene expression in colorectal cancer cell lines should be considered in the "theorization" that the use of pharmacological CDK inhibitors can be used as anti-cancer drugs. 6- Page 6, 2nd para.: The beginning of the last sentence of this paragraph: (...) testing of the first CDK inhibitor, Flavopiridol, several (...) should be rewritten as : (...) testing of this first CDK pharmacological inhibitor, several



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

other (...) for more clarity. 7- Page 6, last line: the title should be "pharmacological CDK inhibitors"
8- Page 8, last sentence: It should be specified that these clinical studies are phase I as: Phase i clinical studies (...). 9- The Fig 1 is somewhat redundant to Table 1. One way to improve its usefulness would be to complete the Fig by adding the cellular CDK inhibitors. 10- Page 9, end of 1st para.: the beginning of the sentence "For example, in flavopiridol, the first ever CDK-inhibitor tested in clinical trials has (...)" is redundant to the previous page. The sentence should begin like "For example, flavopiridol has (...)". 11- Page 11, third line: the sentence "(...) on CDK inhibitors, it wise to investigate (...)" should be completed (would be wise?).